IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?

Br J Haematol. 2020 Aug;190(3):314-317. doi: 10.1111/bjh.16710. Epub 2020 May 17.

Authors

Michael Leisch^{1

2}, Richard Greil^{1

2

3}, Lisa Pleyer^{1

2

3}

Affiliations

¹ Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.
² Paracelsus Medical University, Salzburg, Austria.
³ Cancer Cluster Salzburg, Salzburg, Austria.

No abstract available

Publication types

Comment

MeSH terms

Azacitidine
Disease Progression
Humans
Indoleamine-Pyrrole 2,3,-Dioxygenase
Leukemia, Myeloid, Acute*
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / genetics
Pharmaceutical Preparations*
Prognosis

Substances

Indoleamine-Pyrrole 2,3,-Dioxygenase
Pharmaceutical Preparations
Azacitidine